Q1FY22 Earnings Presentation

8 Strides 12 Pharma Net Debt Net debt and Investments Investments in CHC & Biotech Total Net Debt As at March 2021 * 5,948m As at March 2021 * 6,886m As at March 2021 * 12,834m As at June 2021 * 7,530m Change over March 2021 + € 1,582m ]] As at June 2021 * 6,886m As at June 2021 * 14,416m Change over March 2021 +0m Change over March 2021 + * 1,582m Notional impact of ~*310m on Net debt due to appreciation of USD versus INR during the quarter Pharma Net debt represents Net debt, minus Cash investments made in Biotech and CHC business

View entire presentation